Renal malignancies are among the most prevalent pediatric cancers.
The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.
Written by:
Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, Anderson JR, Naranjo A, Perlman EJ. Are you the author?
Division of Oncology, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, District of Columbia.
Reference: Pediatr Blood Cancer. 2012 Dec 19. Epub ahead of print.
doi: 10.1002/pbc.24419
PubMed Abstract
PMID: 23255438
UroToday.com Renal Cancer Section
